HomeBUSINESS
BUSINESS

Janssen Files Guselkumab for Palmoplantar Pustulosis in Japan
(Dec.11.2017)

Janssen Pharmaceutical on December 8 filed an application in Japan, seeking an additional indication for its human monoclonal anti-interleukin (IL)-23 antibody guselkumab for the treatment of palmoplantar pustulosis (PPP) in patients who responded inadequately to existing therapies ...
(LOG IN FOR FULL STORY)

News Calendar